Profile Picture
Rewards
  • Search
  • Chat
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
    • Real Estate
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Time Person of the Year
Television pioneer dies
To sign executive order
Plans to sell chips in China
Air Force confirms fatality
US high-speed rail funding
Teacher assaults student
FBI agent carjacking arrest
Outrage against AI imitation
Contract renewed with agency
Testify on campus antisemitism
‘DWTS’ season 32 winner
Time's Athlete of the Year
$377M jackpot numbers
USWNT victory over China
Australia's economy slows
Weighs third-party run
Enlist in S. Korean military
Amazon slams Microsoft
Win MLB draft lottery
Visits UAE, Saudi Arabia
Regains $3T market cap
Feeling 'much better'
Rays sign Chris Devenski
Signs deal with White Sox
‘The Traitors’ season 2
Skips court hearing
Lakers beat Suns
1 rescued, dozens missing
TX shooting suspect charged
103K jobs added in Nov.
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
3,740 results
hrexecutive
6d
As anti-obesity drug prices soar, how employers can navigate difficult choices
High prices for anti-obesity drugs known as GLP-1 medications, coupled with high employee demand, are giving employers a lot ...
The Messenger on MSN5d
Pfizer Suffers Setback in Weight Loss Trial After Patients Drop Pill Due to Uncomfortable Side Effects
While Wegovy, Ozempic and Zepbound soar, other weight loss medications are struggling.
7don MSN
Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says
Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to ...
3mon
Wegovy weight-loss drugmaker sees profits soar
The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in ...
Reuters5d
Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the ...
Healthline21d
Black People Are Facing Greater Challenges Accessing Anti-Obesity Drugs Like Ozempic and Wegovy
Share on Pinterest Diabetes and obesity disproportionately impact Black people, yet they are facing greater challenges gaining access to GLP-1 medications like Ozempic that could help treat these ...
Futurism2mon
Snack Food CEO Vows to Battle Ozempic
As the popularity of appetite-suppressing drugs like Ozempic and Wegovy continues to skyrocket, one of America's chief snack food overlords is readying himself — and his company's delicious ...
Medindia20d
Medications and their Potential to Cause Increase 'Throat sore'
This section presents medications that are known to potentially lead to 'Throat sore' as a side effect." It's important to note that mild side effects are quite common with medications. Please be ...
Hosted on MSN1mon
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
Is the fervor over Ozempic just a passing fad? It doesn't appear to be the case after Novo Nordisk (NYSE: NVO) announced its results for the first nine months of 2023 on Thursday morning.
The Guardian1mon
Sales soar at Danish firm behind weight-loss drug semaglutide
Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company The maker of blockbuster weight-loss drug semaglutide has reported a steep rise in sales and ...
BBC3mon
Wegovy weight-loss drugmaker sees profits soar
The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in profits on the back of surging demand for the drugs. Net profits were 39 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Get the Bing App
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices